Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications

Drug and Alcohol Dependence

Volumn 144, Issue , 2014, Pages 12-41

  Castaneto, Marisol S ^a,b   Gorelick, David A ^c   Desrosiers, Nathalie A ^a,b   Hartman, Rebecca L ^a,b   Pirard, Sandrine ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

CB1 CB2 agonists; Designer drug; Epidemiology; Pharmacodynamics; Spice; Synthetic cannabinoids

Indexed keywords

ADAMANTOYLINDOLE; ADAMANTYLINDOLE DERIVATIVE; AMIDE; AMINOALKYLIDOLE; AMINOALKYLINDOLE DERIVATIVE; BENZOYLIDOLE; BENZOYLINDOLE DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CYCLOHEXYLPHENOL; CYCLOHEXYLPHENOL DERIVATIVE; DIBENZOPYRAN; DIBENZOPYRAN DERIVATIVE; DRONABINOL; INDAZOLE CARBOXAMIDE; INDAZOLE DERIVATIVE; METHANANDAMIDE; NAPHTHOYLINDOLE; NAPHTHOYLINDOLE DERIVATIVE; NAPHTHOYPYRROLE; NAPHTHYLMETHYLINDENE; NAPHTHYLMETHYLINDOLE; PHENYLACETYLINDOLE; PHENYLACETYLINDOLE DERIVATIVE; PREGABALIN; QUINOLINYL ESTER INDOLE; SYNTHETIC CANNABINOID DERIVATIVE; TETRAMETHYLCYCLOPROPYL KETONE INDOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; CANNABINOID; DESIGNER DRUG; PROTEIN BINDING;

ACUTE KIDNEY FAILURE; AGITATION; ANALGESIA; ANTICONVULSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; BEHAVIOR DISORDER; COGNITIVE DEFECT; DRIVING ABILITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPNEA; EPIDEMIOLOGY; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INTOXICATION; LABORATORY TEST; MORTALITY; MUSCLE DISEASE; NAUSEA AND VOMITING; NONHUMAN; PHARMACODYNAMICS; PRENATAL DRUG EXPOSURE; PSYCHOSIS; RECEPTOR AFFINITY; RESPIRATION DEPRESSION; REVIEW; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TACHYCARDIA; THORAX PAIN; WEIGHT REDUCTION; ANIMAL; METABOLISM; PHYSIOLOGY; SYNTHESIS;

ANIMALS; CANNABINOIDS; DESIGNER DRUGS; DRONABINOL; HUMANS; PROTEIN BINDING; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84908879029     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.08.005     Document Type: Review

References (228)

1. Abalo R., Cabezos P.A., Vera G., Lopez-Miranda V., Herradon E., Martin-Fontelles M.I. Cannabinoid-induced delayed gastricv emptying is selectively increased upon intermittent administration in the rat: role of CB1 receptors. Neurogastroenterol. Motil. 2011, 23:457-467.
2. Acheson S.K., Moore N.L., Kuhn C.M., Wilson W.A., Swartzwelder H.S. The synthetic cannabinoid WIN 55212-2 differentially modulates thigmotaxis but not spatial learning in adolescent and adult animals. Neurosci. Lett. 2011, 487:411-414.
3. Alhadi S., Tiwari A., Vohra R., Gerona R., Acharya J., Bilello K. High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J. Med. Toxicol. 2013, 9:199-206.
4. American Association of Poison Control Centers Synthetic Marijuana Data 2013, http://www.aapcc.org/alerts/synthetic-marijuana/ (accessed 30.01.14).
5. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 2013, APA, Washington, DC. 5th ed.
6. Anaraki D.K., Sianati S., Sadeghi M., Ghasemi M., Javadi P., Mehr S.E., Dehpour A.R. Modulation by female sex hormones of the cannabinoid-induced catalepsy and analgesia in ovariectomized mice. Eur. J. Pharmacol. 2008, 586:189-196.
7. Arevalo-Martin A., Vela J.M., Molina-Holgado E., Borrell J., Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 2003, 23:2511-2516.
8. Army Center for Substance Abuse Program Expansion of Synthetic Cannabinoids To Military Urinalysis Testing 2013, http://acsap.army.mil/Pdf/ALARACT%20310-2013.pdf (accessed 30.12.13).
9. Arnold J.C., Dielenberg R.A., McGregor I.S. Cannabinoids increase conditioned ultrasonic vocalisations and cat odour avoidance in rats: strain differences in drug-induced anxiety. Life Sci. 2010, 87:572-578.
10. Ashton J.C., Friberg D., Darlington C.L., Smith P.F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci. Lett. 2006, 396:113-116.
11. Atwood B.K., Lee D., Straiker A., Widlanski T.S., Mackie K. CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur. J. Pharmacol. 2011, 659:139-145.
12. Aung M.M., Griffin G., Huffman J.W., Wu M.-J., Keel C., Yang B., Showalter V.M., Abood M.E., Martin B.R. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding. Drug Alcohol Depend. 2000, 60:133-140.
13. Auwärter V., Dresen S., Weinmann W., Müller M., Pütz M., Ferreirós N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?. J. Mass Spectrom. 2009, 44:832-837.
14. Balistreri E., Garcia-Gonzalez E., Selvi E., Akhmetshina A., Palumbo K., Lorenzini S., Maggio R., Lucattelli M., Galeazzi M., Distler J.W.H. The cannabinoid WIN55,212-2 abrogates dermal fibrosis in scleroderma bleomycin model. Ann. Rheum. Dis. 2011, 70:695-699.
15. Banerji S., Deutsch C., Bronstein A. Spice aint so nice. Clin. Toxicol. (Phila.) 2010, 48:632.
16. Banister S.D., Wilkinson S.M., Longworth M., Stuart J., Apetz N., English K., Brooker L., Goebel C., Hibbs D.E., Glass M., Connor M., McGregor I.S., Kassiou M. The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. ACS Chem. Neurosci. 2013, 4:1081-1092.
17. Barlas F., Higgins W., Plfieger J., Diecker K. 2011 Department of Defense Health Related Behaviors Survey of Active Duty Military Personnel 2013, http://www.murray.senate.gov/public/_cache/files/889efd07-2475-40ee-b3b0-508947957a0f/final-2011-hrb-active-duty-survey-report.pdf (accessed 01.03.13).
18. Barratt M.J., Cakic V., Lenton S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev. 2013, 32:141-146.
19. Basavarajappa B.S., Subbanna S. CB1 receptor-mediated signaling underlies the hippocampal synaptic, learning and memory deficits following treatment with JWH-081, a new component of spice/K2 preparations. Hippocampus 2013, 24:178-188.
20. Bebarta V.S., Ramirez S., Varney S.M. Spice: a new "legal" herbal mixture abused by young active duty military personnel. Subst. Abuse 2012, 33:191-194.
21. Bell M.R., D'Ambra T.E., Kumar V., Eissenstat M.A., Herrmann J.L., Wetzel J.R., Rosi D., Philion R.E., Daum S.J., Hlasta D.J., et al. Antinociceptive (aminoalkyl)indoles. J. Med. Chem. 1991, 34:1099-1110.
22. Benagiano V., Lorusso L., Flace P., Girolamo F., Rizzi A., Sabatini R., Auteri P., Bosco L., Cagiano R., Ambrosi G. Effects of prenatal exposure to the CB-1 receptor agonist WIN 55212-2 or CO on the GABAergic neuronal systems of rat cerebellar cortex. Neuroscience 2007, 149:592-601.
23. Benford D.M., Caplan J.P. Psychiatric sequelae of Spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics 2011, 52:295.
24. Bernson-Leung M.E., Leung L.Y., Kumar S. Synthetic cannabis and acute ischemic stroke. J. Stroke Cerebrovasc. Dis. 2013, 23:1239-1241.
25. Berry-Caban C.S., Ee J., Ingram V., Berry C.E., Kim E. Synthetic cannabinoid overdose in a 20-year-old male US soldier. Subst. Abuse 2013, 34:70-72.
26. Bhanushali G.K., Jain G., Fatima H., Leisch L.J., Thornley-Brown D. AKI associated with synthetic cannabinoids: a case series. Clin. J. Am. Soc. Nephrol. 2013, 8:523-526.
27. Biscaia M., Fernández B., Higuera-Matas A., Miguéns M., Viveros M.-P., García-Lecumberri C., Ambrosio E. Sex-dependent effects of periadolescent exposure to the cannabinoid agonist CP-55,940 on morphine self-administration behaviour and the endogenous opioid system. Neuropharmacology 2008, 54:863-873.
28. Bosier B., Muccioli G.G., Mertens B., Sarre S., Michotte Y., Lambert D.M., Hermans E. Differential modulations of striatal tyrosine hydroxylase and dopamine metabolism by cannabinoid agonists as evidence for functional selectivity in vivo. Neuropharmacology 2012, 62:2328-2336.
29. Boucher A.A., Hunt G.E., Micheau J., Huang X.F., McGregor I.S., Karl T., Arnold J.C. The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. Int. J. Neuropsychopharmacol. 2011, 14:631-643.
30. Brantley C. Spice, bath salts, salvia divinorum, and huffing: a judge advocate's guide to disposing of designer drugs cases in the military 2012, 15-37. Army Lawyer DA PAM 27-50-467.
31. Breivogel C.S., Griffin G., Di Marzo V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 2001, 60:155-163.
32. Breivogel C.S., Sim L.J., Childers S.R. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J. Pharmacol. Exp. Ther. 1997, 282:1632-1642.
33. Brents L.K., Reichard E.E., Zimmer.man S.M., Moran J.H., Fantegrossi W.E., Prather P.L. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS ONE 2011, 6:e21917.
34. Brents L.K., Zimmerman S.M., Saffell A.R., Prather P.L., Fantegrossi W.E. Differential drug-drug interactions of the synthetic cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy. J. Pharmacol. Exp. Ther. 2013, 346:350-361.
35. Bronstein A.C., Spyker D.A., Cantilena L.R., Rumack B.H., Dart R.C. 2011 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th annual report. Clin. Toxicol. (Phila.) 2012, 50:911-1164.
36. Buchler, I., Hayes, M., Hedge, S., Hockerman, S., Eugene, D., Kortum, S., Rico, J., Tenbrink, R., Wu, K., 2009. Indazole derivatives. US Patent CA 2714573 A1, pp. 1-283.
37. Burgos E., Pascual D., Martin M.I., Goicoechea C. Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests. Eur. J. Pain 2010, 14:40-48.
38. Canning J., Ruha A.-M., Pierce R., Torrey M., Reinhart S. Severe GI distress after smoking JWH-018. Clin. Toxicol. (Phila.) 2010, 48:618.
39. Castaldo P., Magi S., Gaetani S., Cassano T., Ferraro L., Antonelli T., Amoroso S., Cuomo V. Prenatal exposure to the cannabinoid receptor agonist WIN 55,212-2 increases glutamate uptake through overexpression of GLT1 and EAAC1 glutamate transporter subtypes in rat frontal cerebral cortex. Neuropharmacology 2007, 53:369-378.
40. Castellanos D., Singh S., Thornton G., Avila M., Moreno A. Synthetic cannabinoid use: a case series of adolescents. J. Adolesc. Health 2011, 49:347-349.
41. Centers for Disease Control and Prevention Acute kidney injury associated with synthetic cannabinoid use - multiple states, 2012 2013, MMWR Morb. Mortal. Wkly. Rep. 62.
42. Centers for Disease Control and Prevention Notes from the field: severe illness associated with reported use of synthetic marijuana - Colorado, August-September 2013 2013, 1016-1017. MMWR Morb. Mortal. Wkly. Rep. 62.
43. Centers for Disease Control and Prevention Notes from the field: severe illness associated with synthetic cannabinoid use - Brunswick, Georgia, 2013 2013, 939. MMWR Morb. Mortal. Wkly. Rep. 62.
44. Chen B., Bromley-Brits K., He G., Cai F., Zhang X., Song W. Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model. Curr. Alzheimer Res. 2010, 7:255-261.
45. Chopda G.R., Vemuri V.K., Sharma R., Thakur G.A., Makriyannis A., Paronis C.A. Diuretic effects of cannabinoid agonists in mice. Eur. J. Pharmacol. 2013, 721:64-69.
46. Cohen J., Morrison S., Greenberg J., Saidinejad M. Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 2012, 129:e1064-e1067.
47. Cole W. "Spice" traps troops: new synthetic substance not found by most tests have become a problem on post, the military says 2011, http://www.staradvertiser.com/news/hawaiinews/20110425_Spice:traps_troops.html (accessed 15.09.11).
48. Craft R.M., Wakley A.A., Tsutsui K.T., Laggart J.D. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat. J. Pharmacol. Exp. Ther. 2012, 340:787-800.
49. Croxford J.L., Miller S.D. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J. Clin. Invest. 2003, 111:1231-1240.
50. Dableh L.J., Yashpal K., Henry J.L. Physiological evidence of a postsynaptic inhibition of the tail flick reflex by a cannabinoid receptor agonist. Eur. J. Pharmacol. 2009, 602:36-40.
51. Dagon Y., Avraham Y., Link G., Zolotarev O., Mechoulam R., Berry E.M. The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells. Neurobiol. Dis. 2007, 27:174-181.
52. Dalton V., Wang H., Zavitsanou K. HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat. Neurochem. Res. 2009, 34:1343-1353.
53. Dalton V.S., Zavitsanou K. Cannabinoid effects on CB1 receptor density in the adolescent brain: an autoradiographic study using the synthetic cannabinoid HU210. Synapse 2010, 64:845-854.
54. Dalton V.S., Zavitsanou K. Differential treatment regimen-related effects of cannabinoids on D1 and D2 receptors in adolescent and adult rat brain. J. Chem. Neuroanat. 2010, 40:272-280.
55. De Vries T.J., Shaham Y., Homberg J.R., Crombag H., Schuurman K., Dieben J., Vanderschuren L.J.M.J., Schoffelmeer A.N.M. A cannabinoid mechanism in relapse to cocaine seeking. Nat. Med. 2001, 7:1151-1154.
56. del Arco I., Munoz R., Rodriguez De Fonseca F., Escudero L., Martin-Calderon J.L., Navarro M., Villanua M.A. Maternal exposure to the synthetic cannabinoid HU-210: effects on the endocrine and immune systems of the adult male offspring. Neuroimmunomodulation 2000, 7:16-26.
57. Deng H., Gifford A.N., Zvonok A.M., Cui G., Li X., Fan P., Deschamps J.R., Flippen-Anderson J.L., Gatley S.J., Makriyannis A. Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. J. Med. Chem. 2005, 48:6386-6392.
58. Derungs A., Schwaninger A., Mansella G., Bingisser R., Kraemer T., Liechti M. Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol. 2013, 31:164-171.
59. Desai R.I., Thakur G.A., Vemuri V.K., Bajaj S., Makriyannis A., Bergman J. Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists, and noncannabinoid drugs. J. Pharmacol. Exp. Ther. 2013, 344:319-328.
60. Devane W.A., Breuer A., Sheskin T., Jaerbe T.U.C., Eisen M.S., Mechoulam R. A novel probe for the cannabinoid receptor. J. Med. Chem. 1992, 35:2065-2069.
61. Dill J.A., Howlett A.C. Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J. Pharmacol. Exp. Ther. 1988, 244:1157-1163.
62. Effron L. "Bath Salts," "Spice and US Military: Are Service Members Abusing Synthetic Drugs? 2013, http://abcnews.go.com/US/bath-salts-spice-us-military-service-members-abusing/story?id=19621742 (accessed 02.09.13).
63. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend. 2011, 117:152-157.
64. Faircloth J., Khandheria B., Shum S. Case report: adverse reaction to synthetic marijuana. Am. J. Addict. 2012, 21:289-290.
65. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 1995, 48:443-450.
66. Felder C.C., Veluz J.S., Williams H.L., Briley E.M., Matsuda L.A. Cannabinoid agonists stimulate both receptor-mediated and nonreceptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol. Pharmacol. 1992, 42:838-845.
67. Forrester M.B., Kleinschmidt K., Schwarz E., Young A. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum. Exp. Toxicol. 2012, 31:1006-1011.
68. Franklin J.M., Carrasco G.A. Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling. Synapse 2013, 67:145-159.
69. Franklin J.M., Mathew M., Carrasco G.A. Cannabinoid-induced upregulation of serotonin 2A receptors in the hypothalamic paraventricular nucleus and anxiety-like behaviors in rats. Neurosci. Lett. 2013, 548:165-169.
70. Freeman M.J., Rose D.Z., Myers M.A., Gooch C.L., Bozeman A.C., Burgin W.S. Ischemic stroke after use of the synthetic marijuana "spice". Neurology 2013, 81:2090-2093.
71. Friedman L.K., Rudenko V. WIN55, 212 attenuates NMDA but not kainate intra-hippocampal seizures via mglur1(alpha) and cb1 receptors in development. Epilepsy Curr. 2013, 13:478.
72. Ginsburg B.C., Schulze D.R., Hruba L., McMahon L.R. JWH-018 and JWH-073: delta-9-THC like discriminative stimulus effects in monkeys. J. Pharmacol. Exp. Ther. 2011, 340:38.
73. Glue P., Al-Shaqsi S., Hancock D., Gale C., Strong B., Schep L. Hospitalisation associated with use of the synthetic cannabinoid K2. N. Z. Med. J. 2013, 126:18-23.
74. Gonzalez C., Herradon E., Abalo R., Vera G., Perez-Nievas B.G., Leza J.C., Martin M.I., Lopez-Miranda V. Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia - reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS. Diabetes Metab. Res. Rev. 2011, 27:331-340.
75. Goonawardena A.V., Plano A., Robinson L., Platt B., Hampson R.E., Riedel G. A pilot study into the effects of the CB1 cannabinoid receptor agonist WIN55,212-2 or the antagonist/inverse agonist AM251 on sleep in rats. Sleep Disord. 2011, 2011:178469.
76. Gould J. Legal High Becomes Horrible Dream 2010, http://www.armytimes.com/article/20101002/NEWS/10020307/Legal-high-becomes-8216-horrible-dream- (accessed 01.09.11).
77. Gould J. Spice crackdown: Commanders get police powers 2013, http://www.armytimes.com/article/20130527/NEWS/305270010/ (accessed 02.10.13).
78. Grey J., Terry P., Higgs S. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour. Behav. Pharmacol. 2012, 23:551-559.
79. Grigoryev A., Kavanagh P., Melnik A. The detection of the urinary metabolites of 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone (AM-694), a high affinity cannabimimetic, by gas chromatography - mass spectrometry. Drug Test. Anal. 2012, 5:110-115.
80. Grigoryev A., Kavanagh P., Melnik A. The detection of the urinary metabolites of 3-[(adamantan-1-yl)carbonyl]-1-pentylindole (AB-001), a novel cannabimimetic, by gas chromatography-mass spectrometry. Drug Test. Anal. 2012, 4:519-524.
81. Gunderson E.W., Haughey H.M., Ait-Daoud N., Joshi A.S., Hart C.L. Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am. J. Addict. 2012, 21:320-326.
82. Harris C.R., Brown A. Synthetic cannabinoid intoxication: a case series and review. J. Emerg. Med. 2012, 44:360-366.
83. Heath T.S., Burroughs Z., Thompson A.J., Tecklenburg F.W. Acute intoxication caused by a synthetic cannabinoid in two adolescents. J. Pediatr. Pharmacol. Ther. 2012, 17:177-181.
84. Hermanns-Clausen M., Kneisel S., Auwarter V. New drugs of abuse: acute intoxication by smoking herbal products containing synthetic cannabinoids. Clin. Toxicol. (Phila.) 2011, 49:199.
85. Hermanns-Clausen M., Kneisel S., Hutter M., Szabo B., Auwärter V. Acute intoxication by synthetic cannabinoids - four case reports. Drug Test. Anal. 2013, 5:790-794.
86. Hermanns-Clausen M., Kneisel S., Szabo B., Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013, 108:534-544.
87. Higuera-Matas A., Soto-Montenegro M.L., Montoya G.L., Garcia-Vazquez V., Pascau J., Miguens M., Del Olmo N., Vaquero J.J., Garcia-Lecumberri C., Desco M., Ambrosio E. Chronic cannabinoid administration to periadolescent rats modulates the metabolic response to acute cocaine in the adult brain. Mol. Imaging Biol. 2011, 13:411-415.
88. Hill M.N., Gorzalka B.B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur. Neuropsychopharmacol. 2005, 15:593-599.
89. Hill M.N., Gorzalka B.B. Increased sensitivity to restraint stress and novelty-induced emotionality following long-term, high dose cannabinoid exposure. Psychoneuroendocrinology 2006, 31:526-536.
90. Hill M.N., Sun J.C., Tse M.T., Gorzalka B.B. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int. J. Neuropsychopharmacol. 2006, 9:277-286.
91. Hopkins C.Y., Gilchrist B.L. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J. Emerg. Med. 2013, 45:544-546.
92. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54:161-202.
93. Howlett A.C., Berglund B., Melvin L.S. Cannabinoid receptor agonists and antagonists. Curr. Pharm. Des. 1995, 1:343-354.
94. Howlett A.C., Johnson M.R., Melvin L.S., Milne G.M. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. 1988, 33:297-302.
95. Hoyer F., Steinmetz M., Zimmer S., Zimmer A., Nickenig G. Modulation of atherosclerosis via cannabinoid receptor-2 in mice. Eur. Heart J. 2011, 32:516-517.
96. Hu X., Primack B.A., Barnett T.E., Cook R.L. College students and use of K2: an emerging drug of abuse in young persons. Subst. Abuse Treat. Prev. Policy 2011, 6:16.
97. Huffman J.W., Dai D. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg. Med. Chem. Lett. 1994, 4:563-566.
98. Huffman J.W., Mabon R., Wu M.-J., Lu J., Hart R., Hurst D.P., Reggio P.H., Wiley J.L., Martin B.R. 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB1 cannabinoid receptor. Bioorg. Med. Chem. 2003, 11:539-549.
99. Huffman J.W., Szklennik P.V., Almond A., Bushell K., Selley D.E., He H., Cassidy M.P., Wiley J.L., Martin B.R. 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg. Med. Chem. Lett. 2005, 15:4110-4113.
100. Huffman J.W., Zengin G., Wu M.-J., Lu J., Hynd G., Bushell K., Thompson A.L.S., Bushell S., Tartal C., Hurst D.P., Reggio P.H., Selley D.E., Cassidy M.P., Wiley J.L., Martin B.R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl) indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists. Bioorg. Med. Chem. 2005, 13:89-112.
101. Humbert-Claude M., Larrat B., Tanter M., Lenkei Z. Chronic cannabinoid treatment induces connectivity alterations in the juvenile rat brain evidenced by diffusion tensor imaging. Eur. Neuropsychopharmacol. 2013, 23:S275-S276.
102. Hurst D., Loeffler G., McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am. J. Psychiatry 2011, 168:1119.
103. Hutter M., Moosmann B., Kneisel S., Auwärter V. Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism. J. Mass Spectrom. 2013, 48:885-894.
104. Hyatt W.S., Zimmerman S.M., Fantegrossi W.E. Conditioned taste aversion elicited by synthetic cannabinoid JWH-018 in mice is attenuated by pretreatment with phytocannabinoid Delta-9-THC. FASEB J. 2012, 26.
105. Järbe T., Tai S., LeMay B., Nikas S., Shukla V., Zvonok A., Makriyannis A. AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice. Psychopharmacology (Berl.) 2011, 220:417-426.
106. Järbe T.U., LeMay B.J., Halikhedkar A., Wood J., Vadivel S.K., Zvonok A., Makriyannis A. Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats. Psychopharmacology (Berl.) 2014, 231:489-500.
107. Järbe T.U., Ross T., DiPatrizio N.V., Pandarinathan L., Makriyannis A. Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats. Pharmacol. Biochem. Behav. 2006, 85:243-252.
108. Jarbe T.U., Tai S., LeMay B.J., Nikas S.P., Shukla V.G., Zvonok A., Makriyannis A. AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice. Psychopharmacology (Berl.) 2012, 220:417-426.
109. Järbe T.U.C., Deng H., Vadivel S.K., Makriyannis A. Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (δ9-tetrahydrocannabinol) discrimination for rats. Behav. Pharmacol. 2011, 22:498-507.
110. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.-P., Bai G., Zhang X. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J. Clin. Invest. 2005, 115:3104-3116.
111. Jinwala F.N., Gupta M. Synthetic cannabis and respiratory depression. J. Child Adolesc. Psychopharmacol. 2012, 22:459-462.
112. Johnson L.A., Johnson R.L., Alfonzo C. Spice: a legal marijuana equivalent. Mil. Med. 2011, 176:718-720.
113. Johnson M.R., Melvin L.S. The discovery of nonclassical cannabinoid analgesics. Cannabinoids as Therapeutic Agents 1986, 121-145. CRC Press, Boca Raton. R. Mechoulam (Ed.).
114. Kang S., Kim C.H., Lee H., Kim D.Y., Han J.I., Chung R.K., Lee G.Y. Antinociceptive synergy between the cannabinoid receptor agonist WIN 55,212-2 and bupivacaine in the rat formalin test. Anesth. Analg. 2007, 104:719-725.
115. Kelai S., Hanoun N., Aufrere G., Beauge F., Hamon M., Lanfumey L. Cannabinoid-serotonin interactions in alcohol-preferring vs. alcohol-avoiding mice. J. Neurochem. 2006, 99:308-320.
116. Kelly B.C., Wells B.E., Pawson M., Leclair A., Parsons J.T., Golub S.A. Novel psychoactive drug use among younger adults involved in US nightlife scenes. Drug Alcohol Rev. 2013, 32:588-593.
117. Korya, D., Kapoor, A., Labiner, D., 2013. Ischemic stroke in a 28-year-old woman after smoking synthetic THC. Neurology 80, Meeting Abstracts 1.
118. Kronstrand R., Roman M., Andersson M., Eklund A. Toxicological findings of synthetic cannabinoids in recreational users. J. Anal. Toxicol. 2013, 37:534-541.
119. Kwilasz A.J., Negus S.S. Dissociable effects of the cannabinoid receptor agonists Delta9-tetrahydrocannabinol and CP55940 on pain-stimulated versus pain-depressed behavior in rats. J. Pharmacol. Exp. Ther. 2012, 343:389-400.
120. Lapoint J., Le V., Lackey F., Radominska-Pandya A., Moran C., James L.P., Nelson L.S., Hoffman R.S., Moran J.H. Seizures following ingestion of the synthetic cannabinoid JWH-018. Clin. Toxicol. (Phila.) 2011, 49:213-214.
121. Lax P., Altavilla C., Esquiva G., Cuenca N. The synthetic cannabinoid HU210 slows retinal degeneration in p23h rats. Ophthalmic Res. 2013, 50:42.
122. Lee M.K., Choi B.Y., Yang G.Y., Jeon H.J., Kyung H.M., Kwon O.W., Park H.S., Bae Y.C., Mokha S.S., Ahn D.K. Low doses of cannabinoids enhance the antinociceptive effects of intracisternally administered mGluRs groups II and III agonists in formalin-induced TMJ nociception in rats. Pain 2008, 139:367-375.
123. Levin K.H., Copersino M.L., Heishman S.J., Liu F., Kelly D.L., Boggs D.L., Gorelick D.A. Cannabis withdrawal symptoms in non-treatment-seeking adults cannabis smokers. Drug Alcohol Depend. 2010, 111:120-127.
124. Leweke F.M., Schneider M. Chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia: effects of the atypical antipsychotic quetiapine. Int. J. Neuropsychopharmacol. 2011, 14:43-51.
125. Lewis S.E., Paro R., Borriello L., Simon L., Robinson L., Dincer Z., Riedel G., Battista N., Maccarrone M. Long-term use of HU210 adversely affects spermatogenesis in rats by modulating the endocannabinoid system. Int. J. Androl. 2012, 35:731-740.
126. Liang Y.C., Huang C.C., Hsu K.S. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. Neuropharmacology 2007, 53:169-177.
127. Linsenbardt D.N., Boehm S.L. Agonism of the endocannabinoid system modulates binge-like alcohol intake in male C57BL/6J mice: involvement of the posterior ventral tegmental area. Neuroscience 2009, 164:424-434.
128. Liu C., Walker J.M. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain. J. Neurophysiol. 2006, 96:2984-2994.
129. Live H. Spice Scandal Hits U.S. Naval Academy 2011, http://www.huffingtonpost.com/2011/02/01/spice-scandal-hits-us-_n_817009.html (accessed 30.07.11).
130. Locatelli C.A., Lonati D., Giampreti A., Petrolini V., Vecchio S., Rognoni C., Bigi S., Buscaglia E., Mazzoleni M., Manzo L., Papa P., Valli A., Rimondo C., Serpelloni G. New synthetic cannabinoids intoxications in Italy: clinical identification and analytical confirmation of cases. Eur. J. Emerg. Med. 2011, 18:309.
131. Loeffler G., Hurst D. Naval Medical Center San Diego Treats Sailors following Spice Use 2011, http://www.navy.mil/submit/display.asp?story_id=59964 (accessed 31.07.11).
132. Logan B.K., Reinhold L.E., Kacinko S.L. K2 and Beyond: A Synthetic Cannabinoid Primer (K43) 2011, American Academy of Forensic Sciences, Chicago, IL.
133. Logico M. Confessions of Navy Spice Users: Two Sailors Reveal How Spice Ended Their Careers 2012, http://www.navy.mil/submit/display.asp?story_id=66260 (accessed 07.07.12).
134. Lopez H.H., Zappia K., Cushman C.L., Chadwick B. Acute cannabinoid administration attenuates female socio-sexual motivation. Pharmacol. Biochem. Behav. 2010, 94:482-487.
135. Luszczki J.J., Florek-Luszczki M. Synergistic interaction of pregabalin with the synthetic cannabinoid WIN 55,212-2 mesylate in the hot-plate test in mice: an isobolographic analysis. Pharmacol. Rep. 2012, 64:723-732.
136. Luszczki J.J., Misiuta-Krzesinska M., Florek M., Tutka P., Czuczwar S.J. Synthetic cannabinoid WIN 55,212-2 mesylate enhances the protective action of four classical antiepileptic drugs against maximal electroshock-induced seizures in mice. Pharmacol. Biochem. Behav. 2011, 98:261-267.
137. Macri S., Lanuzza L., Merola G., Ceci C., Gentili S., Valli A., Macchia T., Laviola G. Behavioral responses to acute and sub-chronic administration of the synthetic cannabinoid JWH-018 in adult mice prenatally exposed to corticosterone. Neurotox. Res. 2013, 24:15-28.
138. Maguire D.R., Yang W., France C.P. Interactions between mu-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration. J. Pharmacol. Exp. Ther. 2013, 345:354-362.
139. Maguma H., Thayne K., Taylor D.A. Characteristics of tolerance in the guinea pig ileum produced by chronic in vivo exposure to opioid versus cannabinoid agonists. Biochem. Pharmacol. 2010, 80:522-532.
140. Makriyannis A, Deng, H., 2000. Cannabimimetic Indole Derivatives. US Patent Office, Washington, DC.
141. Makriyannis A, Deng, H., 2007. Receptor Selective Cannabimimetic Aminoalkylindoles. US Patent Office, Washington, DC.
142. Manzanedo C., Rodriguez-Arias M., Daza-Losada M., Maldonado C., Aguilar M.A., Minarro J. Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice. Behav. Brain Funct. 2010, 6:19. 10.1186/1744-9081-6-19.
143. McCain K.R., Moran J.H., James L.P., Foster H.R. Adverse effects and confirmatory testing of JWH-018 and JWH-073 following synthetic cannabinoid use. Clin. Toxicol. (Phila.) 2011, 49:519.
144. McGuiness T.M., Newell D. Risky recreation: synthetic cannabinoids have dangerous effects. J. Psychosoc. Nurs. Ment. Health Serv. 2012, 50:16-18.
145. McLaughlin P.J., Lu D., Winston K.M., Thakur G., Swezey L.A., Makriyannis A., Salamone J.D. Behavioral effects of the novel cannabinoid full agonist AM 411. Pharmacol. Biochem. Behav. 2005, 81:78-88.
146. McMahon L.R., Ginsburg B.C., Lamb R.J. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of.DELTA.9-tetrahydrocannabinol in C57BL/6J mice. Psychopharmacology (Berl.) 2008, 198:487-495.
147. McQuade D., Hudson S., Dargan P.I., Wood D.M. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur. J. Clin. Pharmacol. 2012, 69:373-376.
148. Mechoulam R., Lander N., Breuer A., Zahalka J. Synthesis of the individual, pharmacological distinct, enantiomer of a tetrahydrocannabinol derivative. Tetrahedron: Asymmetry 1990, 1:315-318.
149. Mechoulam R., Parker L.A. The endocannabinoid system and the brain. Annu. Rev. Psychol. 2013, 64:21-47.
150. Melvin L.S., Milne G.M., Johnson M.R., Subramaniam B., Wilken G.H., Howlett A.C. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol. Pharmacol. 1993, 44:1008-1015.
151. Merroun I., Errami M., Hoddah H., Urbano G., Porres J.M., Aranda P., Llopis J., Lopez-Jurado M. Influence of intracerebroventricular or intraperitoneal administration of cannabinoid receptor agonist (WIN 55,212-2) and inverse agonist (AM 251) on the regulation of food intake and hypothalamic serotonin levels. Br. J. Nutr. 2009, 101:1569-1578.
152. Miller R.L., Thakur G.A., Stewart W.N., Bow J.P., Bajaj S., Makriyannis A., McLaughlin P.J. Effects of a novel CB1 agonist on visual attention in male rats: role of strategy and expectancy in task accuracy. Exp. Clin. Psychopharmacol. 2013, 21:416-425.
153. Mir A., Obafemi A., Young A., Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011, 128:e1622-e1627.
154. Müller H., Huttner H.B., Köhrmann M., Wielopolski J.E., Kornhuber J., Sperling W. Panic attack after spice abuse in a patient with ADHD. Pharmacopsychiatry 2010, 43. 152,153.
155. Müller H., Sperling W., Kohrmann M., Huttner H.B., Kornhuber J., Maler J.M. The synthetic cannabinoid spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr. Res. 2010, 118:309-310.
156. Musshoff F., Madea B., Kernbach-Wighton G., Bicker W., Kneisel S., Hutter M., Auwärter V. Driving under the influence of synthetic cannabinoids ("spice"): a case series. Int. J. Legal Med. 2013, 128:59-64.
157. Nacca N., Vatti D., Sullivan R., Sud P., Su M., Marraffa J. The synthetic cannabinoid withdrawal syndrome. J. Addict. Med. 2013, 7:296-298.
158. Nakajima J., Takahashi M., Nonaka R., Seto T., Suzuki J., Yoshida M., Kanai C., Hamano T. Identification and quantitation of a benzoylindole (2-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone and a naphthoylindole 1-(5-fluoropentyl-1H-indol-3-yl)-(naphthalene-1-yl)methanone (AM-2201) found in illegal products obtained via the Internet and their cannabimimetic effects evaluated by in vitro [S-35]GTP gamma S binding assays. Forensic Toxicol. 2011, 29:132-141.
159. Nallapaneni A., Liu J., Karanth S., Pope C. Modulation of paraoxon toxicity by the cannabinoid receptor agonist WIN 55,212-2. Toxicology 2006, 227:173-183.
160. Nguyen V.H., Verdurand M., Dedeurwaerdere S., Wang H., Zahra D., Gregoire M.C., Zavitsanou K. Increased brain metabolism after acute administration of the synthetic cannabinoid HU210: a small animal PET imaging study with 18F-FDG. Brain Res. Bull. 2012, 87:172-179.
161. O'Malley P.M., Miech R.A., Bachman J.G., Shulenberg J.E. Monitoring the Future: National Results on Adolescent Drug Use. Overview of Keyfinding 2013 2014, http://www.monitoringthefuture.org/data/data.html (accessed 31.12.13).
162. Onaivi E., Ishiguro H., Gong J., Patel S., Meozzi P., Myers L., Perchuka A., Mora Z., Tagliaferro P., Gardner E., Brusco A., Akinsola B., Hope B., Lujilde J., Inada T., Iwasaki S., Macharia D., Teasenfitz L., Arinami T., Uhl G. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS ONE 2008, 3:e1640. 10.1371/journal.pone.0001640.
163. Ovadia H., Wohlman A., Mechoulam R., Weidenfeld J. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 1995, 34:175-180.
164. Page M.E., Oropeza V.C., Sparks S.E., Qian Y., Menko A.S., Van Bockstaele E.J. Repeated cannabinoid administration increases indices of noradrenergic activity in rats. Pharmacol. Biochem. Behav. 2007, 86:162-168.
165. Pandolfo P., Pamplona F.A., Prediger R.D., Takahashi R.N. Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder, to the locomotor stimulation induced by the cannabinoid receptor agonist WIN 55,212-2. Eur. J. Pharmacol. 2007, 563:141-148.
166. Pant S., Deshmukh A., Dholaria B., Kaur V., Ramavaram S., Ukor M., Teran G.A. Spicy seizure. Am. J. Med. Sci. 2012, 344:67-68.
167. Paquette J.J., Wang H.-Y., Bakshi K., Olmstead M.C. Cannabinoid-induced tolerance is associated with a CB1 receptor G protein coupling switch that is prevented by ultra-low dose rimonabant. Behav. Pharmacol. 2007, 18:767-776.
168. Patton A.L., Chimalakonda K.C., Moran C.L., McCain K.R., Radominska-Pandya A., James L.P., Kokes C., Moran J.H. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J. Forensic Sci. 2013, 58:1676-1680.
169. Peglow S., Buchner J., Briscoe G. Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. Am. J. Addict. 2012, 21:287-288.
170. Pertwee R. Receptors and Pharmacodynamics: Natural and Synthetic Cannabinoids and Endocannabinoids 2004, 103-139. Pharmaceutical Press, London.
171. Pertwee R.G. Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol. 2006, 147(Suppl. 1):S163-S171.
172. Pertwee R.G. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 2010, 17:1360-1381.
173. Pintor A., Tebano M.T., Martire A., Grieco R., Galluzzo M., Scattoni M.L., Pezzola A., Coccurello R., Felici F., Cuomo V., Piomelli D., Calamandrei G., Popoli P. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 2006, 51:1004-1012.
174. Pistis M., Perra S., Pillolla G., Melis M., Muntoni A.L., Gessa G.L. Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol. Psychiatry 2004, 56:86-94.
175. Qamri Z., Preet A., Nasser M.W., Bass C.E., Leone G., Barsky S.H., Ganju R.K. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol. Cancer Ther. 2009, 8:3117-3129.
176. Rahn E., Zvonok A., Makriyannis A., Hohmann A. Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation. AAPS J. 2010, 12:147-157.
177. Rahn E.J., Thakur G.A., Wood J.A.T., Zvonok A.M., Makriyannis A., Hohmann A.G. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol. Biochem. Behav. 2011, 98:493-502.
178. Renard J., Krebs M., Jay T., Le Pen G. Long-term cognitive impairments induced by chronic cannabinoid exposure during adolescence in rats: a strain comparison. Psychopharmacology (Berl.) 2013, 225:781-790.
179. Riebe C.J., Lee T.T., Hill M.N., Gorzalka B.B. Precipitated withdrawal counters the adverse effects of subchronic cannabinoid administration on male rat sexual behavior. Neurosci. Lett. 2010, 472:171-174.
180. Rodgman C., Kinzie E., Leimbach E. Bad Mojo: use of the new marijuana substitute leads to more and more ED visits for acute psychosis. Am. J. Emerg. Med. 2011, 29:232.
181. Rodriguez de Fonseca F.R., Villanua M.A., Munoz R.M., San-Martin-Clark O., Navarro M. Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats. Neuroendocrinology 1995, 61:714-721.
182. Rodriguez J.S., McMahon L.R. Discriminative stimulus effects of the synthetic cannabinoid JWH-018 in rhesus monkeys. FASEB J. 2013, 27.
183. Rominger A., Cumming P., Xiong G., Koller G., Förster S., Zwergal A., Karamatskos E., Bartenstein P., La Fougère C., Pogarell O. Effects of acute detoxification of the herbal blend 'Spice Gold' on dopamine D2/3 receptor availability: a [18F]fallypride PET study. Eur. Neuropsychopharmacol. 2013, 23:1606-1610.
184. Saito T., Namera A., Miura N., Ohta S., Miyazaki S., Osawa M., Inokuchi S. A fatal case of MAM-2201 poisoning. Forensic Toxicol. 2013, 31:333-337.
185. Schneider M., Koch M. Deficient social and play behavior in juvenile and adult rats after neonatal cortical lesion: effects of chronic pubertal cannabinoid treatment. Neuropsychopharmacology 2005, 30:944-957.
186. Schneider M., Schoemig E., Leweke F.M. Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict. Biol. 2008, 13:345-357.
187. Schneir A.B., Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J. Med. Toxicol. 2012, 8:62-64.
188. Schneir A.B., Cullen J., Ly B.T. "Spice" girls: synthetic cannabinoid intoxication. J. Emerg. Med. 2011, 40:296-299.
189. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 1996, 278:989-999.
190. Simmons J., Cookman L., Kang C., Skinner C. Three cases of "spice" exposure. Clin. Toxicol. (Phila.) 2011, 49:431-433.
191. Slipetz D.M., O'Neill G.P., Favreau L., Dufresne C., Gallant M., Gareau Y., Guay D., Labelle M., Metters K.M. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol. Pharmacol. 1995, 48:352-361.
192. Sobolevsky T., Prasolov I., Rodchenkov G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci. Int. 2010, 200:141-147.
193. Solbrig M.V., Fan Y., Hermanowicz N., Morgese M.G., Giuffrida A. A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in rats. Exp. Neurol. 2010, 226:231-241.
194. Substance Abuse and Mental Hearlth Services Administration The DAWN Report: Drug-Related Emergency Department Visits Involving Synthetic Cannabinoids 2012, http://www.samhsa.gov/data/2k12/DAWN105/SR105-synthetic-marijuana.pdf (accessed 01.02.13).
195. Sumariwalla P.F., Gallily R., Tchilibon S., Fride E., Mechoulam R., Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum. 2004, 50:985-998.
196. Tarzia G., Duranti A., Tontini A., Spadoni G., Mor M., Rivara S., Vincenzo Plazzi P., Kathuria S., Piomelli D. Synthesis and structure-activity relationships of a series of pyrrole cannabinoid receptor agonists. Bioorg. Med. Chem. Lett. 2003, 11:3965-3973.
197. Teske J., Weller J.-P., Fieguth A., Rothaemel T., Schulz Y., Troeger H.D. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2010, 878:2659-2663.
198. Thomas S., Bliss S., Malik M. Suicidal ideation and self-harm following K2 use. J. Okla. State Med. Assoc. 2012, 105:430-433.
199. Thornton S.L., Wood C., Friesen M.W., Gerona R.R. Synthetic cannabinoid use associated with acute kidney injury. Clin. Toxicol. (Phila.) 2013, 51:189-190.
200. Tofighi B., Lee J.D. Internet highs - seizures after consumption of synthetic cannabinoids purchased online. J. Addict. Med. 2012, 6:240-241.
201. Tung C.K., Chiang T.P., Lam M. Acute mental disturbance caused by synthetic cannabinoid: a potential emerging substance of abuse in Hong Kong. East Asian Arch. Psychiatry 2012, 22:31-33.
202. Tuv S., Krabseth H., Karinen R., Olsen K., Oiestad E., Vindenes V. Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period. Accid. Anal. Prev. 2014, 62.
203. Uchiyama N., Kikura-Hanajiri R., Matsumoto N., Huang Z.L., Goda Y., Urade Y. Effects of synthetic cannabinoids, cannabicyclohexanol and jwh-018, on electroencephalogram power spectra and locomotor activity in rats. Sleep Biol. Rhythms 2011, 9:342.
204. United Nations Office on Drugs and Crime Synthetic Cannabinoids in Herbal Products 2011, http://www.unodc.org/unodc/en/scientists/synthetic-cannabinoids-in-herbal-products.html (accessed 15.09.11).
205. US Drug Enforcement Administration Schedules of Controlled Substances: Temporary Placement of Four Synthetic Cannabinoids Into Schedule I: Notice of Intent. Fed. Regist. 2014, 79:7577-7582.
206. US Drug Enforcement Administration Establishment of Drug Codes for 26 Substances. Final Rule. Fed. Regist. 2013, 78:664-666.
207. US Drug Enforcement Administration Schedules of Controlled Substances: Temporary Placement of Three Synthetic Cannabinoids Into Schedule I. Final Order. Fed. Regist. 2013, 78:28735-28739.
208. Van Der Veer N., Friday J. Persistent psychosis following the use of spice. Schizophr. Res. 2011, 130:285-286.
209. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
210. Vandrey R., Dunn K.E., Fry J.A., Girling E.R. A survey study to characterize use of spice products (synthetic cannabinoids). Drug Alcohol Depend. 2012, 120:238-241.
211. Vearrier D., Osterhoudt K.C. A teenager with agitation: higher than she should have climbed. Pediatr. Emerg. Care 2010, 26:462-465.
212. Verdurand M., Dalton V.S., Zavitsanou K. GABA(A) receptor density is altered by cannabinoid treatment in the hippocampus of adult but not adolescent rats. Brain Res. 2010, 1351:238-245.
213. Vigano D., Rubino T., Vaccani A., Bianchessi S., Marmorato P., Castiglioni C., Parolaro D. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl.) 2005, 182:527-536.
214. Wegener N., Koch M. Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Res. 2009, 1253:81-91.
215. Werling L.L., Reed S.C., Wade D., Izenwasser S. Chronic nicotine alters cannabinoid-mediated locomotor activity and receptor density in periadolescent but not adult male rats. Int. J. Dev. Neurosci. 2009, 27:263-269.
216. Wiebelhaus J.M., Poklis J.L., Poklis A., Vann R.E., Lichtman A.H., Wise L.E. Inhalation exposure to smoke from synthetic "marijuana" produces potent cannabimimetic effects in mice. Drug Alcohol Depend. 2012, 126:316-323.
217. Wikström M., Thelander G., Dahlgren M., Kronstrand R. An accidental fatal intoxication with methoxetamine. J. Anal. Toxicol. 2013, 37:43-46.
218. Wiley J., Marusich J., Lefever T., Grabenauer M., Moore K., Thomas B. Cannabinoids in disguise: delta-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology 2013, 75:145-154.
219. Wiley J.L., Marusich J.A., Huffman J.W. Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci. 2013, 23:531-534.
220. Wiley J.L., Marusich J.A., Martin B.R., Huffman J.W. 1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice. Drug Alcohol Depend. 2012, 123:148-153.
221. Winstock A.R., Barratt M.J. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend. 2013, 131:106-111.
222. Winstock A.R., Mitcheson L.R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
223. World Anti-Doping Agency 2012 Anti-Doping Testing Report 2012, http://www.wada-ama.org/Documents/Resources/Testing-Figures/WADA-2012-Anti-Doping-Testing-Figures-Report-EN.pdf (accessed 01.05.14).
224. World Anti-Doping Agency The 2011 Prohibited List International Standard 2011, http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/WADA_Prohibited_List_2011_EN.pdf (accessed 02.02.13).
225. World Anti-Doping Agency The 2010 Prohibited List International Standard 2010, http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/WADA_Prohibited_List_2010_EN.pdf (accessed 02.02.13).
226. Yeakel J.K., Logan B.K. Blood synthetic cannabinoid concentrations in cases of suspected impaired driving. J. Anal. Toxicol. 2013, 37:547-551.
227. Young A.C., Schwarz E., Medina G., Obafemi A., Feng S.Y., Kane C., Kleinschmidt K. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am. J. Emerg. Med. 2011, (Epub ahead of print).
228. Zimmermann U.S., Winkelmann P.R., Pilhatsch M., Nees J.A., Spanagel R., Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of "Spice Gold". Dtsch. Arztebl. Int. 2009, 106:464-467.